We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

88 hedge funds and large institutions have $416M invested in Pliant Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 13

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

14% more funds holding

Funds holding: 77 → 88 (+11)

1.08% more ownership

Funds ownership: 84.53% → 85.61% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

19% less capital invested

Capital invested by funds: $512M → $416M (-$96M)

50% less call options, than puts

Call options by funds: $326K | Put options by funds: $655K

Holders
88
Holders Change
+11
Holders Change %
+14.29%
% of All Funds
1.35%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
18
Increased
34
Reduced
13
Closed
7
Calls
$326K
Puts
$655K
Net Calls
-$329K
Net Calls Change
+$483K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$18M
2
FLAM
First Light Asset Management
Minnesota
+$6.15M
3
GIM
Granahan Investment Management
Massachusetts
+$4.34M
4
Morgan Stanley
Morgan Stanley
New York
+$3.05M
5
BlackRock
BlackRock
New York
+$2.16M

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$34M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$3.18M
3
WP
Woodline Partners
California
-$3.04M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$420K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$201K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$1.32M +$1.03M +64,562 +195%
N
27
Nuveen
North Carolina
$1.2M -$66.4K -4,180 -4%
IC
28
Ikarian Capital
Texas
$1.17M – – –
Bank of New York Mellon
29
Bank of New York Mellon
New York
$992K -$16K -1,008 -1%
Millennium Management
30
Millennium Management
New York
$868K +$491K +30,867 +92%
PCM
31
Pentwater Capital Management
Florida
$810K – – –
GCP
32
GSA Capital Partners
United Kingdom
$791K +$520K +32,726 +127%
GC
33
Grace Capital
Massachusetts
$776K +$150K +9,413 +20%
JP Morgan Chase
34
JP Morgan Chase
New York
$727K +$592K +37,268 +225%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$669K -$420K -26,439 -35%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$613K +$722K +45,400 New
EAM
37
Eventide Asset Management
Massachusetts
$574K -$34M -2,140,739 -98%
HF
38
HRT Financial
New York
$530K +$625K +39,298 New
Federated Hermes
39
Federated Hermes
Pennsylvania
$494K +$582K +36,618 New
Russell Investments Group
40
Russell Investments Group
United Kingdom
$431K +$45.6K +2,871 +10%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$421K +$235K +14,796 +90%
Renaissance Technologies
42
Renaissance Technologies
New York
$409K +$4.88K +307 +1%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$393K +$190K +11,955 +70%
Swiss National Bank
44
Swiss National Bank
Switzerland
$370K – – –
Bank of America
45
Bank of America
North Carolina
$350K +$103K +6,468 +33%
AllianceBernstein
46
AllianceBernstein
Tennessee
$324K -$4.77K -300 -1%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$318K +$6.79K +427 +2%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$302K -$6.61K -416 -2%
Deutsche Bank
49
Deutsche Bank
Germany
$206K +$12.4K +780 +5%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$198K – – –
1
2
3 4

PLRX Hedge Fund Activity: Q4 2021 in Review

88 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2021, worth a combined $416M — down 19% from $512M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PLRX positions and 7 closed out — a net gain of 11 holders — while 34 added to existing stakes and 13 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $18M. The largest seller was Eventide Asset Management, cutting an estimated $34M.

  • 88 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2021, up from 77 in Q3 2021.
  • Funds reported $416M of Pliant Therapeutics stock for Q4 2021, down 19% quarter-over-quarter.
  • 18 funds opened new Pliant Therapeutics positions in Q4 2021 and 7 closed out, a net change of +11 holders.
  • The largest Pliant Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $18M added.
  • The largest Pliant Therapeutics seller in Q4 2021 was Eventide Asset Management, an estimated $34M sold.

Based on aggregated 13F filings for Q4 2021.